AAC: Cold-and-flu season a good time to remind consumers about not doubling up on acetaminophen dosing
WASHINGTON — The Acetaminophen Awareness Coalition on Tuesday kicked off its annual “Double Check; Don’t Double Up” campaign, reminding consumers to double check their medicine labels to avoid doubling up on medicines with acetaminophen when treating cold and flu symptoms.
A majority of people (seven-in-10) will use over-the-counter medicines to treat their cold and flu symptoms, and many of these medicines contain acetaminophen.
Acetaminophen is found in more than 600 prescription and OTC medicines, including pain relievers, fever reducers, sleep aids and numerous cough, cold and flu medicines. It is safe and effective when used as directed, but there is a limit to how much can be safely taken in one day. The current maximum dose over a 24-hour period for adults is 4,000 milligrams. Taking more than directed is an overdose and can lead to liver damage.
“People may use a medicine to treat their cold or flu symptoms on top of a medicine they are already taking, not realizing that both might contain acetaminophen,” stated Tolu Akinwale, spokesman and registered pharmacist. “The Acetaminophen Awareness Coalition arms pharmacists with tools and resources to help us remind patients who are taking a prescription medicine with acetaminophen to also check the labels of any over-the-counter medicine they take.”
More than 50 million Americans use acetaminophen weekly. The Coalition is targeting these consumers through outreach to its member and partner networks, educational material distribution with an emphasis on retail pharmacies, and partnerships with online health information sites. Coalition members are urging cold and flu sufferers to follow four key acetaminophen safety steps:
- Always read and follow the medicine label;
- Know if medicines contain acetaminophen, which is listed on the front panel of packaging and in bold type or highlighted in the “active ingredients” section of OTC medicine labels, and sometimes listed as “APAP” or “acetam” on Rx labels;
- Never take two medicines that contain acetaminophen at the same time; and
- Ask your healthcare provider or a pharmacist if you have questions about dosing instructions or medicines that contain acetaminophen.
“Cold and flu season is a very appropriate time to remind consumers to double check their medicine labels and not double up on two medicines with acetaminophen at the same time,” commented Emily Skor, executive director of the Consumer Healthcare Products Association Educational Foundation, a founding organization of the Coalition. “Educating consumers on safe acetaminophen use allows them to safely get the relief they are seeking from this important pain reliever.”
The AAC is a group of leading health, healthcare provider and consumer organizations. The Coalition formed the Know Your Dose campaign to educate consumers about safe acetaminophen use in order to prevent liver damage.
Gryphon Investors acquires majority stake in C. B. Fleet Co.
LYNCHBURG, Va. — Gryphon Investors, a San Francisco-based middle market private equity firm, announced Monday that it has acquired a majority stake in C. B. Fleet Co. Fleet’s management team, along with several additional investors, will hold minority stakes alongside Gryphon.
Fleet Labs, headquartered in Lynchburg, Va., and family-owned since its founding in 1869, operates in the personal healthcare and over-the-counter industry with product lines including Summer’s Eve, Fleet, Norforms, Pedia-Lax, Phazyme and Boudreaux’s. The company has a presence in North America, Asia Pacific and Latin America.
Terms of the deal were not disclosed.
“Fleet Laboratories has a commanding position in the OTC and personal healthcare product areas, which we have closely followed for several years," stated Dennis O'Brien, a partner at Gryphon. "We believe the OTC sector is poised for continued expansion as consumers migrate toward more economical non-prescription products and that Fleet has unique and differentiated capabilities to serve these markets. Additionally, the company’s strong brand advantage in the personal healthcare segment under the leading feminine hygiene brand, Summer’s Eve, is a springboard for strong future growth.”
As part of the transaction, Steve LaMonte, a Gryphon advisor and a senior executive in both OTC and personal healthcare businesses who has held leadership positions at Johnson & Johnson, Pfizer and Schering-Plough, will become chairman of the board. CEO Jeff Rowan and the existing management team will remain with the company.
"Fleet Laboratories has a long history of innovation and responsiveness to customer needs, which is coupled with a growing acceptance and awareness of OTC and personal healthcare products among consumers, resulting in a well-run company with a bright future," commented Keith Stimson, also a Gryphon partner. "We welcome Jeff and his team and look forward to working with them on the growth initiatives that will allow Fleet to continue to deliver exceptional results and reach its full potential as a leading player in its industries. Fleet Laboratories is a true platform that provides an excellent opportunity from which to make numerous add-on acquisitions in desirable categories.”
Houlihan Lokey acted as exclusive financial advisor to Gryphon and TM Capital acted as exclusive financial advisor to Fleet on the transaction. Kirkland & Ellis acted as legal advisor to Gryphon and Hunton & Williams and Edmunds & Williams were the legal advisors to Fleet Labs.
NADDI: NPLEx curbing homegrown methamphetamine production in Alabama
LUTHERVILLE, Md. — The National Association of Drug Diversion Investigators on Friday highlighted the latest results achieved by Alabama's real-time, stop-sale pseudoephedrine tracking system.
The National Precursor Log Exchange system automatically blocks unlawful pseudoephedrine purchases at the point of sale, and helps flag meth suspects for law enforcement. Police officers and narcotics agents often set up NPLEx "watch lists" that notify them via email when a meth suspect attempts to make a PSE purchase. The most recent NPLEx data show that in Alabama, the technology has blocked the sale of 56,050 boxes of medicine containing pseudoephedrine since the start of 2014, keeping 138,225 grams out of the hands of potential meth criminals.
Additionally, Alabama sold 15% fewer boxes of PSE compared to the same period in 2013. The number of individual purchasers was further reduced by 12.5%.
Alabama's NPLEx system works in concert with the state's drug offender block list, which prohibits drug offenders from being able to purchase PSE-based medicines. Together, the technologies have helped produce a decline in meth labs across the state — from 720 in 2010 to 154 at the end of 2013. That progress is ongoing.
"Alabama is stepping up efforts to take the fight directly to meth criminals, and NPLEx is proving to be an integral part of that," said Charles Cichon, executive director of NADDI. "With a strong foundation provided by tough anti-meth laws, the state has already made some great gains in this battle. These NPLEx numbers show meth cooks and their associates are taking notice. As NPLEx helps Alabama law enforcement officials curb domestic methamphetamine production, they will be able to focus further on the even greater threat of imported meth from Mexico."
Loading Post Please Wait...